812 related articles for article (PubMed ID: 30284120)
41. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.
Page AT; Clifford RM; Potter K; Schwartz D; Etherton-Beer CD
Br J Clin Pharmacol; 2016 Sep; 82(3):583-623. PubMed ID: 27077231
[TBL] [Abstract][Full Text] [Related]
42. A medication review and deprescribing method for hospitalised older patients receiving multiple medications.
McKean M; Pillans P; Scott IA
Intern Med J; 2016 Jan; 46(1):35-42. PubMed ID: 26387783
[TBL] [Abstract][Full Text] [Related]
43. The effects of in-hospital deprescribing on potential prescribing omission in hospitalized elderly patients with polypharmacy.
Kaminaga M; Komagamine J; Tatsumi S
Sci Rep; 2021 Apr; 11(1):8898. PubMed ID: 33903645
[TBL] [Abstract][Full Text] [Related]
44. Rationalizing prescription via deprescribing in oncology practice.
Raju B; Chaudhary RK; L A; Babu A; Sandeep A; Mateti UV
J Oncol Pharm Pract; 2023 Dec; 29(8):2007-2013. PubMed ID: 37847585
[TBL] [Abstract][Full Text] [Related]
45. Rational deprescribing in the elderly.
Williams S; Miller G; Khoury R; Grossberg GT
Ann Clin Psychiatry; 2019 May; 31(2):144-152. PubMed ID: 31046036
[TBL] [Abstract][Full Text] [Related]
46. Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Hall RK; Blumenthal JB; Doerfler RM; Chen J; Diamantidis CJ; Jaar BG; Kusek JW; Kallem K; Leonard MB; Navaneethan SD; Sha D; Sondheimer JH; Wagner LA; Yang W; Zhan M; Fink JC;
Am J Kidney Dis; 2021 Dec; 78(6):837-845.e1. PubMed ID: 34029681
[TBL] [Abstract][Full Text] [Related]
47. Deprescribing in Older Adults With Cardiovascular Disease.
Krishnaswami A; Steinman MA; Goyal P; Zullo AR; Anderson TS; Birtcher KK; Goodlin SJ; Maurer MS; Alexander KP; Rich MW; Tjia J;
J Am Coll Cardiol; 2019 May; 73(20):2584-2595. PubMed ID: 31118153
[TBL] [Abstract][Full Text] [Related]
48. The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care.
McDonald EG; Wu PE; Rashidi B; Forster AJ; Huang A; Pilote L; Papillon-Ferland L; Bonnici A; Tamblyn R; Whitty R; Porter S; Battu K; Downar J; Lee TC
J Am Geriatr Soc; 2019 Sep; 67(9):1843-1850. PubMed ID: 31250427
[TBL] [Abstract][Full Text] [Related]
49. Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist's geriatric assessment.
Bužančić I; Držaić M; Kummer I; Ortner Hadžiabdić M; Brkić J; Fialová D
Sci Rep; 2024 Mar; 14(1):6235. PubMed ID: 38485992
[TBL] [Abstract][Full Text] [Related]
50. Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol.
Ramsdale E; Mohamed M; Holmes HM; Zubkoff L; Bauer J; Norton SA; Mohile S
J Geriatr Oncol; 2024 Mar; 15(2):101687. PubMed ID: 38302299
[TBL] [Abstract][Full Text] [Related]
51. Tackling potentially inappropriate prescriptions in older adults: development of deprescribing criteria by consensus from experts in Colombia, Argentina, and Spain.
De Las Salas R; Vaca-González C; Eslava-Schmalbach J; Torres-Espinosa C; Figueras A
BMC Geriatr; 2023 Oct; 23(1):682. PubMed ID: 37864147
[TBL] [Abstract][Full Text] [Related]
52. Older peoples' attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia.
Qi K; Reeve E; Hilmer SN; Pearson SA; Matthews S; Gnjidic D
Int J Clin Pharm; 2015 Oct; 37(5):949-57. PubMed ID: 26047944
[TBL] [Abstract][Full Text] [Related]
53. Deprescribing in multi-morbid older people with polypharmacy: agreement between STOPPFrail explicit criteria and gold standard deprescribing using 100 standardized clinical cases.
Curtin D; Dukelow T; James K; O'Donnell D; O'Mahony D; Gallagher P
Eur J Clin Pharmacol; 2019 Mar; 75(3):427-432. PubMed ID: 30421220
[TBL] [Abstract][Full Text] [Related]
54. New horizons in deprescribing for older people.
Woodford HJ; Fisher J
Age Ageing; 2019 Nov; 48(6):768-775. PubMed ID: 31595290
[TBL] [Abstract][Full Text] [Related]
55. Deprescribing in Older Adults With Cancer and Limited Life Expectancy: An Integrative Review.
Brokaar EJ; van den Bos F; Visser LE; Portielje JEA
Am J Hosp Palliat Care; 2022 Jan; 39(1):86-100. PubMed ID: 33739162
[TBL] [Abstract][Full Text] [Related]
56. How "age-friendly" are deprescribing interventions? A scoping review of deprescribing trials.
Wang J; Shen JY; Conwell Y; Podsiadly EJ; Caprio TV; Nathan K; Yu F; Ramsdale EE; Fick DM; Mixon AS; Simmons SF
Health Serv Res; 2023 Feb; 58 Suppl 1():123-138. PubMed ID: 36221154
[TBL] [Abstract][Full Text] [Related]
57. Active deprescribing program in chronic kidney disease patients undergoing haemodialysis.
George JS; Joseph R; Thomas ETA; John GP; Siby A; Nair MM
Nephrology (Carlton); 2021 Nov; 26(11):890-897. PubMed ID: 34240512
[TBL] [Abstract][Full Text] [Related]
58. Interventions to reduce polypharmacy and optimize medication use in older adults with cancer.
Barlow A; Prusak ES; Barlow B; Nightingale G
J Geriatr Oncol; 2021 Jul; 12(6):863-871. PubMed ID: 33353854
[TBL] [Abstract][Full Text] [Related]
59. Deprescribing: a new goal focused on the patient.
Machado-Alba JE; Gaviria-Mendoza A; Machado-Duque ME; Chica L
Expert Opin Drug Saf; 2017 Feb; 16(2):111-112. PubMed ID: 27984921
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial.
Nguyen-Soenen J; Rat C; Gaultier A; Schirr-Bonnans S; Tessier P; Fournier JP
BMC Health Serv Res; 2022 Feb; 22(1):219. PubMed ID: 35177042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
